Previously recorded as Neuron Systems, Inc. (to 2013)
35 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Jan 2027
Next term end
18
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2034 · Medium confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends no later than Jan 2027 · Medium confidence
Also notable
Ends Oct 2038 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Jul 2029 · High confidence
Also notable
Ends Aug 2039 · Medium confidence
Toxic Aldehyde Related Diseases and Treatment
US 11,701,331
Cited by 17 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2034.
Deuterated Compounds and Uses Thereof
US 11,459,300
Cited by 20 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2036.
Compositions and Methods of Treating Retinal Disease
US 8,940,721
Cited by 55 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Treatment of inflammatory disorders
US 11,040,039
Cited by 39 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2038.
Combination Treatment of Ocular Inflammatory Disorders and Diseases
US 11,129,823
Cited by 41 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2037.
Compositions and Methods for the Treatment of Macular Degeneration
US 9,814,701
Cited by 51 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Compositions and methods of treating retinal disease
US 8,940,764
Cited by 52 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Polymorphic Compounds and Uses Thereof
US 11,312,692
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 11,701,331) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Polymorphic Compounds and Uses Thereof (US 10,414,732) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 3 fees due Apr 1 to 17, 2027 · next Apr 1
- 1 fee due Jun 19, 2027The maintenance fee for Deuterated Compounds and Uses Thereof (US 11,845,722) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 10,543,181) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 2 fees due Aug 4 to 27, 2027 · next Aug 4
- 1 fee due Sep 17, 2027The maintenance fee for Toxic Aldehyde Related Diseases and Treatment (US 10,588,874) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 30 US 10,111,862 Novel Traps in the Treatment of Macular Degeneration · lapsed on the fee record
What they patent
The largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Toxic Aldehyde Related Diseases and Treatment | 8 in force | to Jan 2034 |
| Deuterated Compounds and Uses Thereof | 5 in force | to Aug 2036 |
| Ophthalmic Formulations of Methotrexate | 3 in force | to May 2042 |
| Polymorphic Compounds and Uses Thereof (2021) | 2 in force | to Jun 2041 |
| Treatment of inflammatory disorders | 2 in force | to Oct 2038 |
| Compositions and Methods for the Treatment of Macular Degeneration | 2 in force | to Jul 2033 |
| Compositions and Methods of Treating Retinal Disease | 2 in force | to Jul 2028 |
| Methotrexate Treatment Methods | 1 in force | to Dec 2042 |
| Process for Preparation of Aldehyde Scavenger and Intermediates | 1 in force | to Oct 2041 |
| Pharmaceutical Formulations and Uses Thereof | 1 in force | to Oct 2041 |
| Polymorphic Compounds and Uses Thereof (2021) | 1 in force | to Jan 2041 |
| Formulations for Treatment of Dry Eye Disease | 1 in force | to Jan 2040 |
| Ophthalmic Formulations and Uses Thereof | 1 in force | to Jan 2040 |
| Combination Treatment of Ocular Inflammatory Disorders and Diseases | 1 in force | to May 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,940,721 | Compositions and Methods of Treating Retinal Disease In force · Medium confidence | In force | Medium confidence | |
| US 7,973,025 | Compositions and Methods of Treating Retinal Disease In force · High confidence | In force | High confidence | |
| US 8,940,764 | Compositions and methods of treating retinal disease In force · High confidence | In force | High confidence | |
| US 12,097,188 | Compositions and Methods for the Treatment of Macular Degeneration In force · High confidence | In force | High confidence | |
| US 9,814,701 | Compositions and Methods for the Treatment of Macular Degeneration In force · High confidence | In force | High confidence | |
| US 9,604,997 | Peri-Carbinols held by Aldexa Therapeutics, Inc. In force · High confidence | In force | High confidence | |
| US 9,687,481 | Toxic Aldehyde Related Diseases and Treatment In force · High confidence | In force | High confidence | |
| US 10,213,395 | Toxic Aldehyde Related Diseases and Treatment In force · High confidence | In force | High confidence | |
| US 10,543,181 | Toxic Aldehyde Related Diseases and Treatment In force · High confidence | In force | High confidence | |
| US 10,588,874 | Toxic Aldehyde Related Diseases and Treatment In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 35: 8 patents ended · 9 applications pending · 18 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.